Expert Perspective
5m Read
October 17, 2025
ANTIMICROBIAL STEWARDSHIP
Article
5m Read
November 14, 2025
ANTIMICROBIAL STEWARDSHIP
Main Menu
-
Solutions
Back
Cepheid’s Solutions
-
Global Access
-
Testing Everywhere
Back
Testing Everywhere
-
Antibiotic Stewardship
-
Customized Testing for Your Institution
-
Knowing MORE Matters
-
-
Insights
Back
Cepheid’s Insights
-
Webinars
Back
Webinars
-
Cepheid RADAR
Back
Cepheid RADAR
-
Support
Back
Support Center
-
Documents & Technical Resources
-
Troubleshooting and How-tos
-
MyCepheid and Order Support
-
Contact Us
Back
Contact Us
-
-
About Us
Back
About Cepheid
-
Mission and History
Back
Mission and History
-
Our Leadership
Back
Our Leadership
-
Events
Back
Events
-
Distributors
Back
Distributors
-
Business Development Opportunities
-
Innovate with Cepheid
-
Meet the Cepheid Bike
-
News
Back
News
-
Careers
Back
Careers
-
The Need
- The emergence and global spread of carbapenemase producing Enterobacterales (CPE) is of great concern to health services worldwide1
- Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs2
- CPE are multi-drug resistant organisms that can cause serious infections and require interventions in healthcare settings to prevent spread3
- ECDC and CDC recommend comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms3,4
1 Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF. Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2018 Apr 3;66(8):1290-1297. doi: 10.1093/cid/cix893. PMID: 29165604; PMCID: PMC5884739.
2 Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. http://www.sciencedirect.com/science/article/pii/S0196655316303431
3 CDC Healthcare Facilities: Information about CRE https://www.cdc.gov/hai/organisms/cre/cre-facilities.html
4 ECDC RAPID RISK ASSESSMENT. Carbapenem-resistant Enterobacteriaceae–second update. 26 Sept. 2019. Accessed June 2020 https://www.ecdc.europa.eu/sites/portal/files/documents/carbapenem-resistant-enterobacteriaceae-risk-assessment-rev-2.pdf
2 Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. http://www.sciencedirect.com/science/article/pii/S0196655316303431
3 CDC Healthcare Facilities: Information about CRE https://www.cdc.gov/hai/organisms/cre/cre-facilities.html
4 ECDC RAPID RISK ASSESSMENT. Carbapenem-resistant Enterobacteriaceae–second update. 26 Sept. 2019. Accessed June 2020 https://www.ecdc.europa.eu/sites/portal/files/documents/carbapenem-resistant-enterobacteriaceae-risk-assessment-rev-2.pdf
The Solution
- Detection and differentiation of patients with the Xpert Carba-R test can quickly alert clinicians and infection preventionists to the presence of gene sequences associated with carbapenem non-susceptibility
- apid detection and differentiation of the IMP, NDM, or VIM metallo-beta-lactamase gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy
- Rectal and perirectal swabs assist with infection control measures*
- On-demand identification of the most prevalent carbapenemase gene families enables healthcare systems to prevent onward transmission throughout the patient pathway and facilitates more efficient bed management for improved hospital flow5
5 Corless C. et al. Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting. IPIP. 2020 May;3(2):100011.
*With rectal/perirectal swabs, the test is intended as an aid to infection control and is not intended to guide or monitor treatment.
https://www.cepheiddml.com/dam/assetdetails/asset:6e9c30eb-ff54-425c-8043-89b7cac129fb/false?inav=false):
*With rectal/perirectal swabs, the test is intended as an aid to infection control and is not intended to guide or monitor treatment.
https://www.cepheiddml.com/dam/assetdetails/asset:6e9c30eb-ff54-425c-8043-89b7cac129fb/false?inav=false):
The Impact
- Reduced turnaround time enables rapid infection control measure to reduce transmission6,7
- Minimize the number of bed-days lost due to CPE compared to culture5
- Decrease in CPE colonization and infection rates with fast PCR results8
5 Corless C. et al. Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting. IPIP. 2020 May;3(2):100011.
6 Jin S, Lee JY, Park JY, Jeon MJ. Xpert Carba-R assay for detection of carbapenemase-producing organisms in patients admitted to emergency rooms. Medicine (Baltimore). 2020 Dec 11;99(50):e23410.
7 Ambretti S et al. Total integration of cultural and molecular testing for CPE screening with liquid based microbiology (LBM). Poster presented at ECCMID. 2018 21-24 April. Madrid, Spain.
8 Zhou M, Kudinha T, Du B, Peng J, Ma X, Yang Y, Zhang G, Zhang J, Yang Q, Xu YC. Active Surveillance of Carbapenemase-Producing Organisms (CPO) Colonization With Xpert Carba-R Assay Plus Positive Patient Isolation Proves to Be Effective in CPO Containment. Front Cell Infect Microbiol. 2019 May 14;9:162. doi: 10.3389/fcimb.2019.00162. PMID: 31157176; PMCID: PMC6528581.
6 Jin S, Lee JY, Park JY, Jeon MJ. Xpert Carba-R assay for detection of carbapenemase-producing organisms in patients admitted to emergency rooms. Medicine (Baltimore). 2020 Dec 11;99(50):e23410.
7 Ambretti S et al. Total integration of cultural and molecular testing for CPE screening with liquid based microbiology (LBM). Poster presented at ECCMID. 2018 21-24 April. Madrid, Spain.
8 Zhou M, Kudinha T, Du B, Peng J, Ma X, Yang Y, Zhang G, Zhang J, Yang Q, Xu YC. Active Surveillance of Carbapenemase-Producing Organisms (CPO) Colonization With Xpert Carba-R Assay Plus Positive Patient Isolation Proves to Be Effective in CPO Containment. Front Cell Infect Microbiol. 2019 May 14;9:162. doi: 10.3389/fcimb.2019.00162. PMID: 31157176; PMCID: PMC6528581.